SEC Form 4 · accession 0001140361-16-070522

NOVELION THERAPEUTICS INC. · NVLN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 17, 2016

Accepted (ET)

Jun 21, 2016 · 9:10 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000827809

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F1,F2	$1.43	Jun 17, 2016	A	100,000	A	—	Jun 17, 2026	Common stock	100,000	100,000	D
Phantom Stock^{F3,F7,F4,F5,F6}	—	Jun 17, 2016	A	12,800	A	—	—	Common stock	12,800	56,800	D

F1Option exercise price reflects the closing price of the Issuer's common stock on the NASDAQ Stock Market on the June 17, 2016 grant date.
F2The options vest and become exercisable in thirty-six (36) successive and equal monthly installments from the June 17, 2016 grant date. These options were awarded pursuant to the Issuer's 2000 Incentive Stock Plan, as amended and restated..
F3Deferred Stock Units ("DSUs") are payable in cash. The DSUs were awarded pursuant to the Issuer's Directors' Deferred Share Unit Plan.
F4Each DSU, when converted to cash, will be equivalent to the market value of one share of the Issuer's common stock at the time the conversion takes place.
F5The DSUs vest in thirty-six (36) successive and equal monthly installments beginning on the first day of the first month after the June 17, 2016 grant date.
F6The DSUs have no fixed expiration date. Any vested DSUs are payable in cash upon the Reporting Person's departure from the Board of Directors of the Issuer, with any unvested DSUs expiring on such date.
F7Reflects the aggregate amount of DSUs granted to the Reporting Person to date, of which 43,389 DSUs have vested.